Breaking News From ADA 2020


This page was last updated at 9:20am pm PT June 16, 2020.

Editor’s Note: this article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along on twitter at #ADA2020

Tuesday, June 16, 2020 

  • A 22-year follow up on the Diabetes Prevention Program Outcomes Study (DPPOS) indicates a continued significant reduction in the participants’ risk of developing type 2 diabetes. The trial, which was conducted from 1996 to 2001, sought to determine the success of either an intensive lifestyle change program or treatment with metformin to prevent or delay the development of type 2 diabetes in those who were high-risk. Though metformin is an approved drug to treat type 2 diabetes, it is not approved for use in the United States to prevent the disease. However, it is approved in other countries. 22 years later, 75 percent of the participants, who are still alive, have continued to be evaluated. Since the start of the study, individuals in the lifestyle intervention group had a reduced risk of 25 percent of developing type 2 diabetes. Those in the metformin group had an 18 percent reduced risk. The DPPOS study is the largest prevention and longest duration study that continues to actively follow its participants.
  • New rapid-acting insulin Lyumjev from Lilly receives FDA approval for type 1 and type 2 diabetes. More information to come on the specific time to action, prescribing information indicates that it should be taken at meals or up to twenty minutes following meals, and is designed to manage after-meal spikes better than Humalog or similar insulins. It is not yet approved for use in insulin pumps or for children.

Monday, June 15 2020

  • Results from the Trends in Glycemic Control among Youth with Diabetes: The SEARCH for Diabetes in Youth Study revealed that despite the increased availability of diabetes technology, new therapies and more aggressive control targets, today’s young adults and youth have worse glycemic control than previous youth and young adult groups from 2002-2007. Data shows these new groups currently aren’t meeting A1C recommendations. Youth and young adults with type 1 diabetes had an average A1c with 8.7 percent, while those with type 2 diabetes had an estimated average A1c of 8.5 percent. “Given the evidence highlighting the benefits of tight glycemic control, this study reinforces the need for interventions that combine the use of diabetes technology with effective behavioral and social approaches to improve A1C levels,” said the study’s lead author Faisal Malik, MD, MSHS, assistant professor of pediatrics at the University of Washington School of Medicine, investigator at the Center for Child Heath, Behavior and Development at Seattle Children’s Research Institute, and a pediatric endocrinologist at Seattle Children’s Hospital.
  • Analysis of data from the large international DAPA-HF trial showed that the SGLT-2 inhibitor, dapagliflozin, may reduce the onset of type 2 diabetes when used in patients with heart failure. Data showed that dapagliflozin reduced new-onset diabetes by 32 percent with 4.9 percent of patients developing type 2 diabetes compared to 7.1 percent in the placebo group. Participants who developed diabetes had higher average A1C levels, greater body mass index and lower eGFR at the beginning of the study than those who did not develop diabetes. SGLT-2 inhibitors are oral agents designed to help lower blood glucose by preventing glucose from being absorbed in the kidney. The end result is glucose is excreted through urine.
  • Abbott announced that the FDA has approved the FreeStyle Libre 2 System—it is approved for adults and children 4 and up in the United States. The FreeStyle Libre 2 is a 14-day continuous glucose monitor (CGM) system that transmits data every minute and now includes customizable high and low alerts without the need to scan the device. The Abbott announcement says it will be “a third of the cost of other CGMs.”

Sunday, June 14 2020

  • A new study shows minority patients in states with Medicaid expansion experience fewer leg amputations. Data revealed the odds of a major amputation among non-white Medicaid beneficiaries decreased by 17.3 percent in early-adopter states and increased by 1 percent in non-adopter states. The research also indicated patients were seeking medical treatment earlier and were able to prevent amputations. Existing research shows more than half of people with diabetes-related lower-extremity amputation die within five years, a rate higher than most cancer-related deaths. It’s estimated up to one-third of patients with diabetes will develop a foot ulcer, the most common reason for foot and leg amputation.

Saturday, June 13 2020

Friday, June 12 2020

Thursday, June 11 2020


Click here for complete coverage of ADA 2020 from Beyond Type 2.

WRITTEN BY Beyond Type 2 Editorial Team, POSTED 06/11/20, UPDATED 10/04/22

This piece was authored collaboratively by the Beyond Type 2 Editorial Team.